In this large series, the investigators evaluated the short-and long-term safety of infliximab in
patients with Crohn's disease. Using pharmacy records, 500 patients with Crohn's disease …

In this large series, the investigators evaluated the short-and long-term safety of infliximab in
patients with Crohn's disease. Using pharmacy records, 500 patients with Crohn's disease …

Background & Aims: The aim of this study was to evaluate the short-and long-term safety of
infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records …

The study by Lichtenstein et al. analyzed the long-term safety of infliximab in patients with
Crohn's disease using data of the large Crohn's Therapy, Resource, Evaluation, and …

OBJECTIVE: The aim of this study was to report the clinical outcome and adverse events in
the first 100 patients with refractory inflammatory and/or fistulizing Crohn's disease treated …

OBJECTIVE: To determine whether the clinical efficacy and safety of infliximab in diverse
clinical referral practices was similar to that seen in the randomized, controlled clinical trials …

Background The aim of this study was to evaluate the short-and long-term safety experience
of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. Methods The …

The aim of this study was to report the 1-year clinical experience with infliximab treatment for
Crohn's disease (CD) in the Netherlands. All 73 CD patients receiving infliximab infusions …

Introduction: Infliximab is an established treatment for steroid‐resistant and fistulating
Crohn's disease. Although efficacy has been shown in clinical trials, financial implications …

The 1998 release of infliximab in the United States for the treatment of moderate-to-severe
Crohn's disease (CD) and Crohn's fistulas truly represented a milestone for the medical …